중동 및 아프리카 폐암 검진 소프트웨어 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

중동 및 아프리카 폐암 검진 소프트웨어 시장 – 2029년까지의 산업 동향 및 예측

  • Healthcare IT
  • Published Report
  • Aug 2022
  • MEA
  • 350 Pages
  • 테이블 수: 205
  • 그림 수: 27

>중동 및 아프리카 폐암 검진 소프트웨어 시장, 제공 모드(클라우드 기반 솔루션, 온프레미스 솔루션 및 웹 기반 솔루션), 제품(폐암 검진 방사선 솔루션, 폐암 검진 환자 관리 소프트웨어, 결절 관리 소프트웨어, 데이터 수집 및 보고, 환자 조정 및 워크플로, 폐 결절 컴퓨터 지원 감지, 병리학 및 암 병기 분류, 통계적 감사 보고, 검진 PAC, 실무 관리 및 감사 로그 추적), 유형(컴퓨터 지원 검진 및 기존 검진), 응용 프로그램( 비소세포 폐암(NSCLC) 및 소세포 폐암(SCLC)), 플랫폼(독립형 및 통합), 구매 모드(기관 및 개인), 최종 사용자(종양 센터, 병원, 외래 수술 센터 및 기타), 유통 채널(직접 입찰 및 제3자 유통업체) - 업계 동향 및 2029년까지의 예측.

중동 및 아프리카 폐암 검진 소프트웨어 시장

중동 및 아프리카 폐암 검진 소프트웨어 시장 분석 및 규모

폐암 사망률 통제는 의료 시설의 주요 관심사 중 하나입니다. 공공 및 민간 기관은 사망률을 통제하기 위한 검진 프로그램을 시작하기 위한 이니셔티브를 취하고 있습니다. 또한, 회사는 환자 데이터 관리를 용이하게 하고 엄격한 데이터 개인 정보 보호 지침으로 더 나은 치료를 제공하기 위한 고급 소프트웨어를 출시하고 있습니다.

중동 및 아프리카 폐암 검진 소프트웨어 시장

중동 및 아프리카 폐암 검진 소프트웨어 시장

폐암 유병률 증가, 폐암에 대한 사람들의 인식 증가, 정부 이니셔티브 증가, 검진 프로그램 수 증가는 시장 성장을 견인하는 주요 요인 중 일부입니다. 또한, 주요 시장 참여자의 인공지능(AI) 기반 솔루션과 전략적 이니셔티브의 발전은 폐암 검진 소프트웨어 분야에서 기회를 창출하고 있습니다.

그러나 데이터 개인정보 보호 문제와 비숙련 노동력 부족이 예측 기간 동안 시장 성장을 방해할 것으로 예상됩니다.

Data Bridge Market Research는 중동 및 아프리카 폐암 검진 소프트웨어 시장이 2029년까지 835,450달러 규모에 도달할 것으로 예상하며, 예측 기간 동안 CAGR은 14.9%라고 분석했습니다. 클라우드 기반 솔루션은 시장에서 가장 큰 배송 모드 세그먼트를 차지합니다. 시장 보고서는 또한 가격 분석, 특허 분석 및 기술 발전에 대한 심층적인 내용을 다룹니다.              

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020 (2019-2014로 사용자 정의 가능)

양적 단위

수익은 천 달러, 가격은 달러로 표시됨

다루는 세그먼트

By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributors)

Countries Covered

U.A.E., Saudi Arabia, Israel, Egypt, South Africa, and rest of Middle East and Africa

Market Players Covered

PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmbH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, and Aidence.com

Market Definition

Lung cancer screening is identifying stages of lung cancer using different technologies and software. Lung cancer screening using CT is the most recommended technique for screening lung cancer. The rising use of this technique is expected to accelerate the need for advanced software for lung cancer screening. This software helps to manage patients’ participation in lung screening programs and provides an efficient way for healthcare professionals to collect, curate, and transfer data to clinicians and patients. In addition, this software enables in the identification of patients at risk and automates the flow of data with integrated electronic health records.

Middle East and Africa Lung Cancer Screening Software Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • Increase in prevalence of lung cancer cases globally

Lung cancer is a leading cause of death in men and women. According to World Cancer Research Fund International, lung cancer is the second most common cancer worldwide. It is the most common cancer in men and second most common in women. There were more than 2.2 thousand new cases of lung cancer in 2020. Increasing prevalence of lung cancer cases creates need to adopt lung cancer screening software for early diagnosis and acts as a driving factor for the market growth.

  • Increase in awareness regarding the benefits of early diagnosis and frequent screening

The rising awareness programs of lung cancer by public, non-profit, and private organizations are anticipated to boost the market growth. These initiatives aim to prevent diseases, reduce stigma and prejudice, and promote research. The awareness among the population regarding lung cancer has increased. Because there are many awareness programs by different organizations, people know about lung cancer that can be cured if diagnosed early. Thus, raising awareness among populations is driving market growth.

  • Government initiatives were undertaken to implement screening programs for various diseases

The burden of cancer continues to increase globally and has great financial, emotional, and physical stress on health systems, products, families, and individuals. In countries with strong health systems, the survival rate of many types of cancer is improved due to survivorship, quality care, increased awareness, and accessible early detection. Centers for Disease Control and Prevention, U.S., tribes, and the U.S.-Pacific islands and territories through the National Comprehensive Cancer Control Program (NCCCP) are to form or support alliances to combat cancer in their communities. Due to these initiatives, more audiences are educated and more consciously dispersed, pushing the global audience to take further precautions and practice preventive examinations, promoting the market.

  • Growing number of screening programs across the globe

Screening is an effective method of detecting early-stage cancer. There is an increasing trend in lung cancer incidences in developing countries. Although there are regular recommendations for screening for breast and cervical cancer, it is not the same in case of lung cancer. Most countries or institutions have initiated the feasibility and disease screening of Low-Dose Computed Tomography (LDCT) for lung cancer. The increasing number of lung cancer screening has created an opportunity for the market players. Hence, the increasing diagnostic rate acts as a driving factor for market growth.

Opportunity

  • Rising collaborations, mergers & acquisitions among the market players

The companies operating in the market are adopting several strategies, including mergers and acquisitions, product launches, agreements, pipeline development, collaborations, and market expansion among others, to boost their business in various dimensions. These strategic decisions by the companies are expected to offer significant opportunities for the market players operating in the market.

Restraints/Challenges

  • Issues related to the availability of software

There are certain issues/barriers related to effective and efficient lung cancer screening and the availability of lung cancer screening software in developing nations. Issues are competing demands for time, knowledge about lung cancer screening, evolving attitudes about the effectiveness of screening, nihilism related to historically poor lung cancer treatment outcomes, and limited training and requirement approval for local authorities or country medical device regulatory body. All these issues delay launches and availability of the product. Also, the demand for lung cancer screening software is hampered due to technical issues related to the available software thereby, acting as a restraint for market growth.

Post-COVID-19 Impact on Middle East and Africa Lung Cancer Screening Software Market

COVID-19 created a major impact on various industries as almost every country opted for the shutdown of every facility except the ones dealing in the essential goods segment. The government took some strict actions such as the shutdown of facilities and sale of non-essential goods, blocking international trade, and many more to prevent the spread of COVID-19. The only business which was running during this pandemic situation was the essential services that were allowed to open and run the processes.

COVID-19 created new and unfamiliar challenges for healthcare providers to deliver patient care. Many non-essential but important services such as lung cancer screening were temporarily suspended to protect the health of staff and patients. Healthcare institutions faced unprecedented challenges regarding scheduling, patient monitoring, and follow-up of patient-service communication to ensure continuity of care during COVID-19 and when services could be continued safely. COVID-19 created new challenges for lung cancer screening programs, in many cases, delaying screening by several months and creating more difficulties for management and scheduling teams. Although the COVID-19 crisis shed new light on the importance of respiratory assistance, it will hopefully have a major impact on reducing stigma of screening for cancer. There are more than 10,000,000 eligible patients in the U.S. who are eligible for lung cancer screening, less than 5 percent of whom are actively enrolled in the screening program. COVID-19 created a negative impact on the market.

However, the lung cancer screening software companies are struggling and continuously taking different strategic decisions to control the situation. The players are involved in strategic activities such as partnerships, collaborations, and mergers & acquisitions among others to improve the technology involved in the market. With this, the companies will bring advanced and accurate solutions to the market. In addition, the government initiatives to boost digitization across industries have also led to market growth.

Recent Developments

  • In July 2022, GE Healthcare launched their latest product and most advanced ultrasound, the next-generation Voluson Expert 22. This latest addition to GE Healthcare’s award-winning Women’s Health portfolio utilizes graphic-based beam former technology, which produces higher quality images and offers greater flexibility in imaging functions. With this product, the company made its position much stronger in the area of products and service providers to healthcare institutions.
  • In October 2021, Thynk Health announced a partnership with Infervision, to fight lung cancer with the world’s most advanced technologies. It offers an opportunity for lung cancer screening and pulmonary nodule management. With this partnership, the company increased its market presence.

Middle East and Africa Lung Cancer Screening Software Market Scope

Middle East and Africa lung cancer screening software market is segmented into eight notable segments based on mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Delivery

  • Cloud Based Solutions
  • On-Premise Solutions
  • Web Based Solutions

On the basis of mode of delivery, the market is segmented into cloud based solutions, on premise solutions, and web based solutions.

Product

  • Lung Cancer Screening Radiology Solution
  •  Lung Cancer Screening Patient Management Software
  •  Nodule Management Software
  •  Data Collection and Reporting
  •  Patient Coordination and Workflow 
  •  Lung Nodule Computer Aided Detection
  •  Pathology and Cancer Staging
  •  Statistical Audit Reporting
  •  Screening PACS
  •  Practice Management 
  •  Audit Log Tracking  

On the basis of product, the market is segmented into lung cancer screening radiology solution, lung cancer screening patient management software, nodule management software, data collection and reporting, patient coordination and workflow, lung nodule computer aided detection, pathology and cancer staging, statistical audit reporting, screening PACS, practice management, and audit log tracking.

Type

  • Computer-Assisted Screening
  •  Traditional Screening

On the basis of type, the market is segmented into computer-assisted screening and traditional screening.

Application

On the basis of application, the market is segmented into Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Platform

  • Standalone
  • Integrated

On the basis of platform, the market is segmented into standalone and integrated.

Purchase Mode

  • Institutional
  • Individual

On the basis of purchase mode, the market is segmented into individual and institutional.

End User

최종 사용자를 기준으로 시장은 병원, 종양학 센터, 외래 수술 센터 및 기타로 구분됩니다.

유통 채널

  • 직접 입찰
  • 제3자 유통업체

유통 채널을 기준으로 시장은 직접 입찰과 제3자 유통업체로 구분됩니다.

폐암 검진 소프트웨어

중동 및 아프리카 폐암 검진 소프트웨어 시장 지역 분석/통찰력

중동 및 아프리카 시장을 분석하고, 위에 언급된 대로 배송 방식, 제품, 유형, 애플리케이션, 플랫폼, 구매 방식, 최종 사용자 및 유통 채널을 기반으로 시장 규모에 대한 통찰력과 추세를 제공합니다.

이 시장 보고서에서 다루는 국가는 UAE, 사우디 아라비아, 이스라엘, 이집트, 남아프리카 공화국, 그리고 중동과 아프리카의 나머지 지역입니다. 사우디 아라비아는 지속적인 전략적 파트너십과 이 지역의 주요 핵심 기업의 존재와 같은 요인으로 인해 시장을 지배합니다. 게다가, 이 지역의 일부 저개발 국가는 의료 부문에서 기술 서비스를 이용할 수 없어서 이 지역의 시장 성장이 더디게 되었습니다.  

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 추세 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세의 영향 및 무역 경로가 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 중동 및 아프리카 폐암 검진 소프트웨어 시장 점유율 분석

중동 및 아프리카 폐암 검진 소프트웨어 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 중동 및 아프리카의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 제공된 위의 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

이 시장에서 활동하는 주요 기업으로는 PenRad Technologies Inc., Koninklijke Philips NV, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmBH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft, Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, Aidence.com 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET

1.4 LIMITATION

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 REGULATIONS & REIMBURSEMENT

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN PREVALENCE OF LUNG CANCER CASES MIDDLE EAST & AFRICALY

6.1.2 INCREASE IN AWARENESS REGARDING THE BENEFITS OF EARLY DIAGNOSIS AND FREQUENT SCREENING

6.1.3 GOVERNMENT INITIATIVES WERE UNDERTAKEN TO IMPLEMENT SCREENING PROGRAMS FOR VARIOUS DISEASES

6.1.4 GROWING NUMBER OF SCREENING PROGRAMS ACROSS THE GLOBE

6.1.5 TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF HEALTHCARE

6.2 RESTRAINTS

6.2.1 ISSUES RELATED TO THE AVAILABILITY OF SOFTWARE

6.2.2 SCARCITY OF TECHNICALLY KNOWLEDGEABLE PROFESSIONALS FOR CANCER DIAGNOSIS

6.2.3 LACK OF FUNDING AND OTHER RESOURCES FROM VARIOUS REGIONS FOR CANCER AND ASSOCIATED DISORDERS

6.3 OPPORTUNITIES

6.3.1 RISING COLLABORATIONS, MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS

6.3.2 INCREASING INVESTMENTS IN HEALTHCARE SEGMENTS

6.3.3 MULTIPLE BENEFITS ASSOCIATED WITH LUNG CANCER SCREENING SOFTWARE

6.4 CHALLENGES

6.4.1 HIGH COST OF SCREENING SOFTWARE AND RELATED SERVICES

6.4.2 INCREASING CHALLENGES RELATED TO THE DEVELOPMENT OF LUNG CANCER SCREENING SOFTWARE

6.4.3 INCREASING COMPETITION IN THE MARKET

7 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY

7.1 OVERVIEW

7.2 CLOUD BASED SOLUTIONS

7.3 ON-PREMISE SOLUTIONS

7.4 WEB BASED SOLUTIONS

8 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 LUNG CANCER SCREENING RADIOLOGY SOLUTION

8.2.1 ON-PREMISE SOLUTIONS

8.2.2 WEB BASED SOLUTIONS

8.2.3 CLOUD BASED SOLUTIONS

8.3 LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE

8.3.1 CLOUD BASED SOLUTIONS

8.3.2 ON-PREMISE SOLUTIONS

8.3.3 WEB BASED SOLUTIONS

8.4 NODULE MANAGEMENT SOFTWARE

8.4.1 CLOUD BASED SOLUTIONS

8.4.2 ON-PREMISE SOLUTIONS

8.4.3 WEB BASED SOLUTIONS

8.5 DATA COLLECTION AND REPORTING

8.5.1 CLOUD BASED SOLUTIONS

8.5.2 WEB BASED SOLUTIONS

8.5.3 ON-PREMISE SOLUTIONS

8.6 PATIENT COORDINATION AND WORKFLOW

8.6.1 CLOUD BASED SOLUTIONS

8.6.2 ON-PREMISE SOLUTIONS

8.6.3 WEB BASED SOLUTIONS

8.7 LUNG NODULE COMPUTER AIDED DETECTION

8.7.1 ON-PREMISE SOLUTIONS

8.7.2 CLOUD BASED SOLUTIONS

8.7.3 WEB BASED SOLUTIONS

8.8 PATHOLOGY AND CANCER STAGING

8.8.1 CLOUD BASED SOLUTIONS

8.8.2 ON-PREMISE SOLUTIONS

8.8.3 WEB BASED SOLUTIONS

8.9 STATISTICAL AUDIT REPORTING

8.9.1 CLOUD BASED SOLUTIONS

8.9.2 ON-PREMISE SOLUTIONS

8.9.3 WEB BASED SOLUTIONS

8.1 SCREENING PACS

8.10.1 CLOUD BASED SOLUTIONS

8.10.2 ON-PREMISE SOLUTIONS

8.10.3 WEB BASED SOLUTIONS

8.11 PRACTICE MANAGEMENT

8.11.1 CLOUD BASED SOLUTIONS

8.11.2 ON-PREMISE SOLUTIONS

8.11.3 WEB BASED SOLUTIONS

8.12 AUDIT LOG TRACKING

8.12.1 CLOUD BASED SOLUTIONS

8.12.2 ON-PREMISE SOLUTIONS

8.12.3 WEB BASED SOLUTIONS

9 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE

9.1 OVERVIEW

9.2 COMPUTER-ASSISTED SCREENING

9.2.1 CLOUD BASED SOLUTIONS

9.2.2 ON-PREMISE SOLUTIONS

9.2.3 WEB BASED SOLUTIONS

9.3 TRADITIONAL SCREENING

9.3.1 CLOUD BASED SOLUTIONS

9.3.2 ON-PREMISE SOLUTIONS

9.3.3 WEB BASED SOLUTIONS

10 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 NON-SMALL CELL LUNG CANCER (NSCLC)

10.2.1 CLOUD BASED SOLUTIONS

10.2.2 ON-PREMISE SOLUTIONS

10.2.3 WEB BASED SOLUTIONS

10.3 SMALL CELL LUNG CANCER (SCLC)

10.3.1 CLOUD BASED SOLUTIONS

10.3.2 ON-PREMISE SOLUTIONS

10.3.3 WEB BASED SOLUTIONS

11 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM

11.1 OVERVIEW

11.2 STANDALONE

11.2.1 CLOUD BASED SOLUTIONS

11.2.2 ON-PREMISE SOLUTIONS

11.2.3 WEB BASED SOLUTIONS

11.3 INTEGRATED

11.3.1 CLOUD BASED SOLUTIONS

11.3.2 ON-PREMISE SOLUTIONS

11.3.3 WEB BASED SOLUTIONS

12 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE

12.1 OVERVIEW

12.2 INSTITUTIONAL

12.3 INDIVIDUAL

13 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER

13.1 OVERVIEW

13.2 ONCOLOGY CENTERS

13.3 HOSPITALS

13.4 AMBULATORY SURGICAL CENTERS

13.5 OTHERS

14 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDERS

14.3 THIRD PARTY DISTRIBUTOR

15 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION

15.1 MIDDLE EAST & AFRICA

15.1.1 SOUTH AFRICA

15.1.2 SOUTH AFRICA

15.1.3 U.A.E

15.1.4 ISRAEL

15.1.5 EGYPT

15.1.6 REST OF MIDDLE EAST AND AFRICA

16 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 KONINKLIJKE PHILIPS N.V

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 SIEMENS HEALTHCARE GMBH

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 NUANCE COMMUNICATIONS, INC.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 GENRAL ELECTRIC (GE HEALTHCARE)

18.4.1 COMPANY SNAPSHOT

18.4.2 COMPANY SHARE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENTS

18.5 ONCOCYTE CORPORATION

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 AIDENCE.COM

18.6.1 COMPANY SNAPSHOT

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ASTRAZENECA

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 CANON MEDICAL INFORMATICS, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENTS

18.9 CORELINE SOFT, CO., LTD.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENTS

18.1 EON

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 EPIC SYSTEMS CORPORATION

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 F. HOFFMANN-LA ROCHE LTD

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 FUJIFILM HOLDINGS CORPORATION

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 GENESYSTEM

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 HEALTHMYNE

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENTS

18.16 LUNGVIEW

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 MAGVIEW

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENT

18.18 MEDIAN TECHNOLOGIES

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENT

18.19 MEDTRONIC

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 PRODUCT PORTFOLIO

18.19.4 RECENT DEVELOPMENTS

18.2 MEVIS MEDICAL SOLUTIONS AG

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 MYCAREWARE INC.

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENT

18.22 OPTELLUM LTD

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENTS

18.23 PENRAD TECHNOLOGIES INC.

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENT

18.24 REVEALDX

18.24.1 COMPANY SNAPSHOT

18.24.2 PRODUCT PORTFOLIO

18.24.3 RECENT DEVELOPMENT

18.25 THYNK HEALTH

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENT

18.26 VOLPARA SOLUTIONS LIMITED

18.26.1 COMPANY SNAPSHOT

18.26.2 REVENUE ANALYSIS

18.26.3 PRODUCT PORTFOLIO

18.26.4 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

표 목록

TABLE 1 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 2 MIDDLE EAST & AFRICA CLOUD BASED SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 3 MIDDLE EAST & AFRICA ON-PREMISE SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 MIDDLE EAST & AFRICA WEB BASED SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 5 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 6 MIDDLE EAST & AFRICA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7 MIDDLE EAST & AFRICA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 8 MIDDLE EAST & AFRICA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 9 MIDDLE EAST & AFRICA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 10 MIDDLE EAST & AFRICA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 11 MIDDLE EAST & AFRICA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 12 MIDDLE EAST & AFRICA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 13 MIDDLE EAST & AFRICA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 14 MIDDLE EAST & AFRICA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 15 MIDDLE EAST & AFRICA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 16 MIDDLE EAST & AFRICA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 17 MIDDLE EAST & AFRICA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 18 MIDDLE EAST & AFRICA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 19 MIDDLE EAST & AFRICA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 20 MIDDLE EAST & AFRICA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 21 MIDDLE EAST & AFRICA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 22 MIDDLE EAST & AFRICA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 MIDDLE EAST & AFRICA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 24 MIDDLE EAST & AFRICA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 25 MIDDLE EAST & AFRICA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 26 MIDDLE EAST & AFRICA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27 MIDDLE EAST & AFRICA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 28 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 29 MIDDLE EAST & AFRICA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 30 MIDDLE EAST & AFRICA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 31 MIDDLE EAST & AFRICA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 32 MIDDLE EAST & AFRICA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 33 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 34 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 36 MIDDLE EAST & AFRICA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 MIDDLE EAST & AFRICA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 38 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 39 MIDDLE EAST & AFRICA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 MIDDLE EAST & AFRICA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 41 MIDDLE EAST & AFRICA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42 MIDDLE EAST & AFRICA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 43 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 44 MIDDLE EAST & AFRICA INSTITUTIONAL IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 45 MIDDLE EAST & AFRICA INDIVIDUAL IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 46 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 47 MIDDLE EAST & AFRICA ONCOLOGY CENTERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48 MIDDLE EAST & AFRICA HOSPITALS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 49 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 51 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 52 MIDDLE EAST & AFRICA DIRECT TENDERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 53 MIDDLE EAST & AFRICA THIRD PARTY DISTRIBUTOR IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 54 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 55 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 56 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 57 MIDDLE EAST & AFRICA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 58 MIDDLE EAST & AFRICA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 59 MIDDLE EAST & AFRICA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 60 MIDDLE EAST & AFRICA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 61 MIDDLE EAST & AFRICA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 62 MIDDLE EAST & AFRICA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 63 MIDDLE EAST & AFRICA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 64 MIDDLE EAST & AFRICA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 65 MIDDLE EAST & AFRICA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 66 MIDDLE EAST & AFRICA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 67 MIDDLE EAST & AFRICA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 68 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 69 MIDDLE EAST & AFRICA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 70 MIDDLE EAST & AFRICA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 71 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 72 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 73 MIDDLE EAST & AFRICA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 74 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 75 MIDDLE EAST & AFRICA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 76 MIDDLE EAST & AFRICA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 77 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 78 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 79 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 80 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 81 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 82 SAUDI ARABIA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 83 SAUDI ARABIA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 84 SAUDI ARABIA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 85 SAUDI ARABIA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 86 SAUDI ARABIA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 87 SAUDI ARABIA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 88 SAUDI ARABIA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 89 SAUDI ARABIA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 90 SAUDI ARABIA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 91 SAUDI ARABIA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 92 SAUDI ARABIA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 93 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 94 SAUDI ARABIA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 95 SAUDI ARABIA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 96 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 97 SAUDI ARABIA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 98 SAUDI ARABIA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 99 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 100 SAUDI ARABIA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 101 SAUDI ARABIA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 102 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 103 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 104 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 105 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 106 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 107 SOUTH AFRICA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 108 SOUTH AFRICA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 109 SOUTH AFRICA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 110 SOUTH AFRICA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 111 SOUTH AFRICA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 112 SOUTH AFRICA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 113 SOUTH AFRICA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 114 SOUTH AFRICA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 115 SOUTH AFRICA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 116 SOUTH AFRICA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 117 SOUTH AFRICA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 118 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 119 SOUTH AFRICA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 120 SOUTH AFRICA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 121 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 122 SOUTH AFRICA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 123 SOUTH AFRICA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 124 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 125 SOUTH AFRICA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 126 SOUTH AFRICA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 127 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 128 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 129 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 130 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 131 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 132 U.A.E LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 133 U.A.E LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 134 U.A.E NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 135 U.A.E DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 136 U.A.E PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 137 U.A.E LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 138 U.A.E PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 139 U.A.E STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 140 U.A.E SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 141 U.A.E PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 142 U.A.E AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 143 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 144 U.A.E COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 145 U.A.E TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 146 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 147 U.A.E NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 148 U.A.E SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 149 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 150 U.A.E STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 151 U.A.E INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 152 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 153 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 154 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 155 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 156 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 157 ISRAEL LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 158 ISRAEL LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 159 ISRAEL NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 160 ISRAEL DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 161 ISRAEL PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 162 ISRAEL LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 163 ISRAEL PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 164 ISRAEL STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 165 ISRAEL SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 166 ISRAEL PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 167 ISRAEL AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 168 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 169 ISRAEL COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 170 ISRAEL TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 171 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 172 ISRAEL NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 173 ISRAEL SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 174 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 175 ISRAEL STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 176 ISRAEL INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 177 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 178 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 179 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 180 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 181 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 182 EGYPT LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 183 EGYPT LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 184 EGYPT NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 185 EGYPT DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 186 EGYPT PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 187 EGYPT LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 188 EGYPT PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 189 EGYPT STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 190 EGYPT SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 191 EGYPT PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 192 EGYPT AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 193 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 194 EGYPT COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 195 EGYPT TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 196 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 197 EGYPT NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 198 EGYPT SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 199 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 200 EGYPT STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 201 EGYPT INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 202 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 203 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 204 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 205 REST OF MIDDLE EAST AND AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

그림 목록

FIGURE 1 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 11 RISING LUNG CANCER SCREENING PROGRAMS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 CLOUD BASED SOLUTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET

FIGURE 14 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY MODE OF DELIVERY, 2021

FIGURE 15 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY PRODUCT, 2021

FIGURE 16 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: TYPE, 2021

FIGURE 17 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY APPLICATION, 2021

FIGURE 18 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY PLATFORM, 2021

FIGURE 19 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY PURCHASE MODE, 2021

FIGURE 20 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY END USER, 2021

FIGURE 21 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 22 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: SNAPSHOT (2021)

FIGURE 23 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY COUNTRY (2021)

FIGURE 24 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY COUNTRY (2022 & 2029)

FIGURE 25 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY COUNTRY (2021 & 2029)

FIGURE 26 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY MODE OF DELIVERY (2022-2029)

FIGURE 27 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Middle East and Africa Lung Cancer Screening Software Market value is expected USD 835.45 thousand by 2029.
The Middle East and Africa Lung Cancer Screening Software Market is to grow at a CAGR of 14.9% during the forecast by 2029.
The major players operating in the Middle East and Africa Lung Cancer Screening Software Market are PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmbH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, and Aidence.com.
The major countries covered in the Middle East and Africa Lung Cancer Screening Software Market are U.A.E., Saudi Arabia, Israel, Egypt, South Africa, and rest of Middle East and Africa.